Peregrine Pharmaceuticals (NASDAQ:PPHM) took a major hit in September after admitting a trial data mix-up for its top drug candidate bavituximab. Since that day, shares had fallen around 80%. Today however, shares were back on the rise, up a healthy 26% (from a much lower base). In this video, Motley Fool health care analyst Brenton Flynn discusses what could be driving share prices today.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.